$IDXX

IDEXX Laboratories (IDXX) acquired CoVetAI, a veterinary software company, to enhance its diagnostic services. The tool integrates with IDEXX's existing systems and aims to increase diagnostic test usage. IDEXX reported Q2 revenue growth of 10% and 11% in recurring diagnostics, with over 1,600 new analyzers placed. The deal terms were not disclosed, and the long-term impact on earnings is uncertain. IDEXX's forward P/E is 30.86 as of September 18.

IDEXX Laboratories (IDXX) acquired CoVetAI, an AI-driven veterinary workflow software provider. The deal expands IDEXX's offerings, integrating CoVet's tools. IDXX shares closed at $510.73 on Tuesday. Financial terms were not disclosed.

Kingsley Lawrence D sold 2,203 shares of IDEXX LABORATORIES INC /DE (IDXX) at $532.08 ($1.17M total) on 2026-09-04.

IDEXX Laboratories (NASDAQ: IDXX) reported Q3 earnings that exceeded EPS and revenue expectations, raising full-year guidance. The stock rose 15% following the announcement.

IDEXX Laboratories (IDXX) reported Q2 2026 results exceeding earnings estimates, raising its full-year 2026 outlook. Key growth came from the Companion Animal Group, with improved margins. Management projects $5.7B revenue and $1.5B earnings by 2029, an 32% upside from current price. Analysts' views vary, with bearish estimates at $5.5B revenue and $1.5B earnings by 2029.

IDEXX Laboratories (IDXX), a global leader in animal health diagnostics, reported Q2 2026 revenue of $1.22B (up 9.7% YoY) and EPS of $4.07 (up 15.3%). The company raised its full-year outlook. Analysts have a 'Moderate Buy' consensus, with a mean price target of $718.14, suggesting 30.6% upside. IDXX stock is down 14.2% over 52 weeks, underperforming the S&P 500 and healthcare sector.

IDEXX Laboratories (IDXX) is expanding global commercial capabilities to support CAG Diagnostics recurring revenue growth. The company's software ecosystem is a key value driver. Challenges include third-party distribution and foreign exchange movements. IDXX stock has fallen 13.7% over the past year, despite beating earnings estimates for four consecutive quarters. The company expects a 70-basis-point drag on revenue growth due to currency movements in Q3 2026.

IDEXX Laboratories (IDXX) reported Q2 earnings of $4.27 per share, beating estimates. Revenue rose 10% to $1.22B. The company raised its 2026 EPS outlook to $14.69-$14.94. Growth was driven by diagnostics, while U.S. veterinary traffic remained soft. Operating margin expanded to 35%.

IDEXX Laboratories launched the Catalyst proBNP Test, a cardiac assay for cats and dogs, expanding its diagnostics portfolio. The test targets a $4B global market and integrates with VetConnect PLUS, potentially boosting consumables growth. IDEXX projects $5.7B revenue and $1.5B earnings by 2029, requiring 8.7% annual growth. Analysts' optimism hinges on recurring revenue despite risks like U.S. visit trends and competition.

IDEXX (IDXX) reported Q2 2026 results and an earnings call transcript. Premium instrument placements topped 5,200 units, including about 1,600 inVue Dx analyzers. Q2 EPS was $4.27. IDEXX raised full-year revenue guidance to $4,700 million to $4,745 million and EPS to $14.69 to $14.94, citing recurring revenue growth and margin expansion.